EN
Cytek Biosciences, Inc. (NASDAQ:CTKB) Analysts Are Pretty Bullish On The Stock After Recent Results
Last week, you might have seen that Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly result to the market. The early response was not positive, with shares down 4.9% to US$5.83 in the past week. It looks like the results were pretty good overall. While revenues of US$53m were in line with analyst predictions, statutory losses were much smaller than expected, with Cytek Biosciences losing US$0.05 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Cytek Biosciences after the latest results.
Following the latest results, Cytek Biosciences' three analysts are now forecasting revenues of US$222.8m in 2027. This would be an okay 7.3% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 59% to US$0.25. Before this latest report, the consensus had been expecting revenues of US$222.8m and US$0.27 per share in losses. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
View our latest analysis for Cytek Biosciences
The average price target rose 11% to US$6.17, with the analysts signalling that the forecast reduction in losses would be a positive for the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Cytek Biosciences, with the most bullish analyst valuing it at US$7.50 and the most bearish at US$5.00 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Cytek Biosciences' past performance and to peers in the same industry. We would highlight that Cytek Biosciences' revenue growth is expected to slow, with the forecast 5.8% annualised growth rate until the end of 2027 being well below the historical 9.0% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 6.9% annually. So it's pretty clear that, while Cytek Biosciences' revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Cytek Biosciences analysts - going out to 2028, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 1 warning sign for Cytek Biosciences you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.